Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Trial Profile

A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadazolid (Primary) ; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPACT 1
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2018 Results from IMPACT 1 and IMPACT 2 studies, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
    • 19 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top